We observed that CD274, CEACAM1, LGALS9, PVR and TNFRSF14 were significantly different (P < 0.05, Fig. 8E) between two groups, providing a novel insight into immunotherapy for cervical carcinoma patients. Here, TNFRSF14 is linked to cervical carcinoma.